European Archives - Page 8 of 1163 - European Medical Journal

Can Microbiome-Guided Therapy Improve Cystic Fibrosis Outcomes?

A new international trial has investigated the safety and efficacy of tailoring antibiotic treatment for cystic fibrosis exacerbations based on sputum microbiome analysis.

Combined Therapy for Allergic Rhinitis Shows Superior Results

The combination therapy demonstrated a significantly higher response rate (98.28%) compared to loratadine alone (87.93%).

Mitigating the Treatment Gap in Drug-Resistant Epilepsy

For this article, EMJ conducted an interview with Ahmed Abdelmoity, Professor and Director, Division of Neurology, Children’s Mercy…

EMJ Neurology 13 [Supplement 7] 2025

Interview article with Prof. Abdelmoity, discussing the current treatment landscape for patients with drug-resistant epilepsy (DRE)…

New Technique Improves Recovery After Liver Surgery

A recent prospective study explored the effectiveness of using indocyanine green to improve intraoperative detection of bile leakage.

Torn agreement

US withdraws funding from Gavi, the Vaccine Alliance

The US plans to stop its financial contributions to Gavi, the Vaccine Alliance, marking an end to an over 20-year partnership.

AI Achieves High Accuracy in Automated Echocardiogram Interpretation

AI now matches experts in echocardiogram interpretation, promising faster, more accessible heart diagnostics for all patients.

Designing Life-Saving Neonatal Incubators: Interview with James Roberts

Conventional incubators haven’t changed for a long time; it’s been the same basic idea since the 1980s. A lot of people can recognise them…

Rising Bedaquiline Resistance Threatens Tuberculosis Control Efforts

Delayed sputum conversion and poor outcomes are common in patients with bedaquiline-resistant TB, according to a new South African cohort study.

Endometriosis Linked to Increased Risk of Autoimmune Conditions

A large-scale study found that women with endometriosis are nearly twice as likely to be diagnosed with autoimmune diseases like lupus, rheumatoid arthritis, or Hashimoto’s within two years.